Late Breaking Abstract - Mepolizumab effectiveness in severe asthma supported by federated analysis of European SHARP data
J. Kroes (Leeuwarden, Netherlands), R. Alfonso-Cristancho (Brentford, United Kingdom), A. Bansal (Cambridge, United Kingdom), E. Berret (Lausanne, Switzerland), K. Bieksiene (Kaunas, Lithuania), A. Bourdin (Montpellier, France), L. Brussino (Turin, Italy), D. Canhoto (Coimbra, Portugal), C. Cardini (Milan, Italy), G. Celik (Ankara, Turkey), Z. Csoma (Budapest, Hungary), B. Dahlén (Stockholm, Sweden), E. Damadoglu (Ankara, Turkey), K. Eger (Amsterdam, Netherlands), L. Gauquelin (Paris, France), B. Gemicioglu (Istanbul, Turkey), O. Goksel (Izmir, Turkey), S. Graff (Liege, Belgium), E. Heffler (Rozzano MI, Italy), H. Hofstee (Leiden, Netherlands), P. Howarth (Brentford, United Kingdom), R. Jakes (Brentford, United Kingdom), F. Jaun (Liestal, Switzerland), V. Kalinauskaite-Zukauske (Kaunas, Lithuania), P. Kopac (Golnik, Slovenia), N. Kwon (Brentford, United Kingdom), C. Loureiro (Coimbra, Portugal), V. Lozoya García (Madrid, Spain), M. Masoli (Exeter, United Kingdom), M. Paula Rezelj (Golnik, Slovenia), L. Pérez De Llano (Lugo, Spain), S. Popovic-Grle (Zagreb, Croatia), D. Ramos-Barbon (Barcelona, Spain), A. Sà Sousa (Porto, Portugal), K. Samitas (Athens, Greece), F. Schleich (Liege, Belgium), C. Sirena (Milan, Italy), S. Skrgat (Ljubljana, Slovenia), E. Zervas (Athens, Greece), G. Zichnalis (Athens, Greece), E. Bel (Amsterdam, Netherlands), J. Sont (Leiden, Netherlands), S. Hashimoto (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands)
Source: International Congress 2022 – Recent advances in biological treatments for asthma
Session: Recent advances in biological treatments for asthma
Session type: Oral Presentation
Number: 3679
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Kroes (Leeuwarden, Netherlands), R. Alfonso-Cristancho (Brentford, United Kingdom), A. Bansal (Cambridge, United Kingdom), E. Berret (Lausanne, Switzerland), K. Bieksiene (Kaunas, Lithuania), A. Bourdin (Montpellier, France), L. Brussino (Turin, Italy), D. Canhoto (Coimbra, Portugal), C. Cardini (Milan, Italy), G. Celik (Ankara, Turkey), Z. Csoma (Budapest, Hungary), B. Dahlén (Stockholm, Sweden), E. Damadoglu (Ankara, Turkey), K. Eger (Amsterdam, Netherlands), L. Gauquelin (Paris, France), B. Gemicioglu (Istanbul, Turkey), O. Goksel (Izmir, Turkey), S. Graff (Liege, Belgium), E. Heffler (Rozzano MI, Italy), H. Hofstee (Leiden, Netherlands), P. Howarth (Brentford, United Kingdom), R. Jakes (Brentford, United Kingdom), F. Jaun (Liestal, Switzerland), V. Kalinauskaite-Zukauske (Kaunas, Lithuania), P. Kopac (Golnik, Slovenia), N. Kwon (Brentford, United Kingdom), C. Loureiro (Coimbra, Portugal), V. Lozoya García (Madrid, Spain), M. Masoli (Exeter, United Kingdom), M. Paula Rezelj (Golnik, Slovenia), L. Pérez De Llano (Lugo, Spain), S. Popovic-Grle (Zagreb, Croatia), D. Ramos-Barbon (Barcelona, Spain), A. Sà Sousa (Porto, Portugal), K. Samitas (Athens, Greece), F. Schleich (Liege, Belgium), C. Sirena (Milan, Italy), S. Skrgat (Ljubljana, Slovenia), E. Zervas (Athens, Greece), G. Zichnalis (Athens, Greece), E. Bel (Amsterdam, Netherlands), J. Sont (Leiden, Netherlands), S. Hashimoto (Amsterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands). Late Breaking Abstract - Mepolizumab effectiveness in severe asthma supported by federated analysis of European SHARP data. 3679
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|